PR positive

About

Biomarker type: Protein expression

Marker: Progesterone receptor (PR)

Unit: status

Equality: =

Value: Positive

Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
FDA (2) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
FDA (2) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
FDA (4) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
FDA (4) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
FDA (4) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
FDA (4) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
FDA (4) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant
FDA (4) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant
FDA (2) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib
FDA (2) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib
FDA (2) HC (1) HER2-negative, PIK3CA oncogenic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
FDA (2) HC (1) ER positive, HER2-negative, PIK3CA oncogenic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
FDA (2) HC (1) HER2-negative, PIK3CA oncogenic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) ER positive, HER2-negative, PIK3CA oncogenic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) AKT1 oncogenic variants, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) AKT1 oncogenic variants, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) AKT1 amplification, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) AKT1 amplification, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) ER positive, HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) ER positive, HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) ER positive, HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) ER positive, HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
FDA (2) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant
FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant
FDA (2) PR positive Invasive Breast Carcinoma Fulvestrant
FDA (2) ER positive, PR positive Invasive Breast Carcinoma Fulvestrant
FDA (4) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib
FDA (4) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib
FDA (4) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib
FDA (4) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
FDA (2) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
FDA (2) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib
FDA (2) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib
FDA (2) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib
FDA (2) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib
FDA (2) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib
FDA (2) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib
FDA (2) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Sacituzumab govitecan
FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Sacituzumab govitecan
FDA (2) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
FDA (2) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
FDA (2) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
FDA (2) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
FDA (4) HC (1) HER2-negative, PIK3CA oncogenic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
FDA (4) HC (1) ER positive, HER2-negative, PIK3CA oncogenic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
HC (1) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Neratinib
HC (1) HER2-positive, PR positive Invasive Breast Carcinoma Neratinib
FDA (2) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
FDA (2) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
FDA (2) HER2-negative, PR positive Non-Small Cell Lung Cancer Datopotamab deruxtecan
FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Datopotamab deruxtecan
FDA (2) HER2-low, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
FDA (2) ER positive, HER2-low, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
FDA (2) HER2-ultralow, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
FDA (2) ER positive, HER2-ultralow, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Anastrozole, Palbociclib, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Anastrozole, Palbociclib, Pertuzumab, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Exemestane, Palbociclib, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Exemestane, Palbociclib, Pertuzumab, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib, Pertuzumab, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib, Pertuzumab, Trastuzumab